Skip to main content
. 2017 Oct 4;6(11):2497–2506. doi: 10.1002/cam4.1203

Figure 3.

Figure 3

Kaplan–Meier survival curves for patients presenting with metastatic disease, stratified by receipt of pelvic radiotherapy. The median OS was 21.6 months versus 12.5 months in favor of pelvic RT in the unadjusted cohort (left, P < 0.01). The median OS was 17.6 months versus 14.5 months in favor of pelvic RT in the propensity‐score matched cohort (right, P < 0.01).